Company releases positive topline results from phase III trial assessing Filsuvez gel as a treatment for dystrophic and junctional Epidermolysis Bullosa (EB)

This study, the largest in EB, comparing Filsuvez, against a control gel, demonstrated statistically significant accelerated wound healing according to the proportion of patients with complete closure of the target wound within 45 days of treatment.

SPS commentary:

EB is a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. Regulatory submissions in the U.S. and the EU are expected to be filed by the end of the first quarter of 2021.

Biospace Inc.